The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial

American Heart Journal

Volumn 149, Issue 5, 2005, Pages 869-875

  Berger, Peter B ^a   Best, Patricia J M ^a   Topol, Eric J ^b   White, Jennifer ^e   Dibattiste, Peter M ^d   Chan, Albert W ^b   Kristensen, Steen D ^f   Herrmann, Howard C ^c   Moliterno, David J ^g  

^a MAYO CLINIC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ASTRAZENECA   (United Kingdom)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CREATININE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIA; KIDNEY FUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY STENOSIS; CREATININE; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RENAL INSUFFICIENCY; TREATMENT OUTCOME; TYROSINE;

EID: 19344373842     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.12.002     Document Type: Article

References (22)

1. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
2. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N. Engl. J. Med. 330 1994 956 961
3. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N. Engl. J. Med. 336 1997 1689 1696
4. The IMPACT-II Investigators Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 1997 1422 1428
5. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
6. The EPISTENT Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 1998 87 92
7. M.H. Rubenstein, L.C. Harrell, and B.V. Sheynberg Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 102 2000 2966 2972
8. D.J. Moliterno, and E.J. Topol A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study Am. Heart J. 140 2000 722 726
9. E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N. Engl. J. Med. 344 2001 1888 1894
10. D.W. Cockroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. H.H. Ting, N.K. Tahirkheli, and P.B. Berger Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure Am. J. Cardiol. 87 2001 630 633
12. Renal Data System USRDS 1997 annual report 1997 National Institute of Diabetes and Digestive and Kidney Diseases Bethesda (Md) 91 101 [publication no 97-3176]
13. C.A. Herzog, J.Z. Ma, and A.J. Collins Poor long-term survival after acute myocardial infarction among patients on long-term dialysis N. Engl. J. Med. 339 1998 799 805
14. L.A. Szczech, D.N. Reddan, and W.F. Owen Differential survival after coronary revascularization procedures among patients with renal insufficiency Kidney Int. 60 2001 292 299
15. J.F. Mann, H.C. Gerstein, and J. Pogue Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann. Intern. Med. 134 2001 629 636
16. L. Gruberg, G. Dangas, and R. Mehran Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure Catheter. Cardiovasc. Interv. 55 2002 66 72
17. A.M. Lincoff, R.M. Califf, and D.J. Moliterno Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators N. Engl. J. Med. 341 1999 319 327
18. A.M. Lincoff Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization Am. J. Cardiol. 82 1998 36P 42P
19. C. Le Feuvre, G. Dambrin, and G. Helft Clinical outcome following coronary angioplasty in dialysis patients: a case-control study in the era of coronary stenting Heart 85 2001 556 560
20. R. Sreedhara, I. Itagaki, and R.M. Hakim Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors Am. J. Kidney Dis. 27 1996 355 364
21. M. Liani, F. Salvati, and M. Golato Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia Nephron 72 1996 716
22. B.S. Smith, and P.J. Gandhi Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure J. Thromb. Thrombolysis 11 2001 39 48